NewAmsterdam Pharma Company N.V. Reports Third Quarter Financial Results and European Commission Approval
NewAmsterdam Pharma Company N.V. reported its financial results for the quarter ended September 30, 2026, recognizing revenue of $19.2 million, compared to $0.3 million in the same period in 2025. The revenue increase was primarily due to the recognition of certain regulatory mil
